Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems

Little information exists on the effects of transjugular intrahepatic portosystemic shunts (TIPS) in the management of cirrhotic patients with hepatorenal syndrome (HRS). The current study was aimed to prospectively evaluate the effects of TIPS on renal function and vasoactive systems in patients with type I HRS. Glomerular filtration rate (GFR) (inulin clearance), renal plasma flow (RPF) (para‐aminohippurate clearance), plasma renin activity (PRA), aldosterone (ALDO), norepinephrine (NE), and endothelin (ET) were determined in baseline conditions and at different time intervals after TIPS in 7 patients with type I HRS. TIPS induced a marked reduction of portal pressure gradient (PPG) (20 ± 1 to 10 ± 1 mm Hg; P < .05). Renal function improved in 6 of the 7 patients. Serum creatinine and blood urea nitrogen (BUN) decreased from 5 ± 0.8 and 109 ± 7 to 1.8 ± 0.4 mg/dL and 56 ± 11 mg/dL, respectively (P < .05 for both), and GFR and RPF increased from 9 ± 4 and 103 ± 33 to 27 ± 7 mL/min and 233 ± 40 mL/min, respectively (P < .05 for both), 30 days after TIPS. These beneficial effects on renal function were associated with a significant (P < .05) reduction of PRA (18 ± 5 to 3 ± 1 ng/mL · h), ALDO (279 ± 58 to 99 ± 56 ng/dL), and NE (1,257 ± 187 to 612 ± 197 pg/mL). ET did not change significantly (28 ± 8 to 27 ± 11 pg/mL). Mean survival was 4.7 ± 2 months (0.3‐17 months). Three patients remained alive more than 3 months after TIPS insertion. In conclusion, TIPS improves renal function and reduces the activity of the renin‐angiotensin and sympathetic nervous systems in cirrhotic patients with type I HRS. Nevertheless, the efficacy of TIPS in the management of these patients should be confirmed in controlled investigations.

[1]  D. Häussinger,et al.  Hepatorenal reflex regulating kidney function , 1991, Hepatology.

[2]  N. Grace.  TIPS: the long and short of it. , 1997, Gastroenterology.

[3]  J. D. Morillas,et al.  Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. , 1987, Journal of hepatology.

[4]  G. Klintmalm,et al.  Impact of pretransplant renal function on survival after liver transplantation. , 1995 .

[5]  A. Freedman,et al.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study , 1994, Hepatology.

[6]  T. Sturgis.  Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. , 1995, Journal of clinical gastroenterology.

[7]  J. Rank,et al.  Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt. , 1993, Radiology.

[8]  H. Smulyan,et al.  Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. , 1979, Kidney international.

[9]  J. Rodés,et al.  Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. , 1998, Gastroenterology.

[10]  R. Schrier,et al.  Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of Cirrhosis , 1994, Seminars in liver disease.

[11]  M. Langer,et al.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. , 1995, The New England journal of medicine.

[12]  E. Ring,et al.  Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. , 1993, Transplantation proceedings.

[13]  M. Rössle.  The transjugular intrahepatic portosystemic shunt. , 1996, Journal of hepatology.

[14]  L. Spahr,et al.  Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. , 1995, The American journal of gastroenterology.

[15]  M. Sherman,et al.  Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites , 1995, Annals of Internal Medicine.

[16]  A. Heyrovský,et al.  A new method for the determination of inulin in plasma and urine. , 1956, Clinica chimica acta; international journal of clinical chemistry.

[17]  A. Blei.  Hepatic encephalopathy in the age of TIPS , 1994, Hepatology.

[18]  G. Sanz,et al.  Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction , 1988, Hepatology.

[19]  F. Gordon,et al.  Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. , 1996, Radiology.

[20]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[21]  P. Hayes,et al.  A randomized trial comparing transjugular intrahepatic portosystemic stent‐shunt with variceal band ligation in the prevention of rebleeding from esophageal varices , 1997, Hepatology.

[22]  J. Hoofnagle,et al.  The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. , 1995, Hepatology.

[23]  C. Brun.  A rapid method for the determination of para-aminohippuric acid in kidney function tests. , 1951, The Journal of laboratory and clinical medicine.

[24]  M. Reynaert,et al.  Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation. , 1995, Hepato-gastroenterology.

[25]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[26]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[27]  E. Ring,et al.  Using Transjugular Intrahepatic Portosystemic Shunts to Control Variceal Bleeding before Liver Transplantation , 1992, Annals of Internal Medicine.

[28]  E. Ring,et al.  Treatment of hepatorenal syndrome with the transjugular intrahepatic portosystemic shunt (TIPS) , 1995 .

[29]  W. Rector.  Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. , 2008, Liver.

[30]  W. Jiménez,et al.  Urinary endothelin-like immunoreactivity in patients with cirrhosis. , 1997, Journal of hepatology.

[31]  G. Laffi,et al.  Pathogenesis and Management of the Hepatorenal Syndrome , 1994, Seminars in liver disease.

[32]  A Ochs,et al.  The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. , 1994, The New England journal of medicine.

[33]  M. Maynar,et al.  Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. , 1996, Gastroenterology.

[34]  R. Safirstein,et al.  A hepatorenal depressor reflex: A possible clue to the pathogenesis of the hepatorenal syndrome , 1991, Hepatology.

[35]  J. Llovet,et al.  Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis , 1994, Hepatology.

[36]  J. Lake,et al.  Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function , 1995, Hepatology.

[37]  L. Blendis,et al.  Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance , 1995, Hepatology.

[38]  M. Kerstein,et al.  The hepatorenal syndrome: recovery after portacaval shunt. , 1975, Annals of surgery.

[39]  L. Blendis,et al.  Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? , 1992, Journal of hepatology.

[40]  B. Sangro,et al.  Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters , 1995, Hepatology.